- Home
- NPWR vs MREO Comparison
NPWR vs MREO Comparison
Compare NPWR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- MREO
- Stock Information
- Founded
- NPWR 2010
- MREO 2015
- Country
- NPWR United States
- MREO United Kingdom
- Employees
- NPWR N/A
- MREO N/A
- Industry
- NPWR Industrial Machinery/Components
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- NPWR Energy
- MREO Health Care
- Exchange
- NPWR Nasdaq
- MREO Nasdaq
- Market Cap
- NPWR 665.3M
- MREO 577.6M
- IPO Year
- NPWR N/A
- MREO N/A
- Fundamental
- Price
- NPWR $12.67
- MREO $3.53
- Analyst Decision
- NPWR Hold
- MREO Strong Buy
- Analyst Count
- NPWR 2
- MREO 4
- Target Price
- NPWR $9.50
- MREO $7.50
- AVG Volume (30 Days)
- NPWR 754.9K
- MREO 690.6K
- Earning Date
- NPWR 11-11-2024
- MREO 11-12-2024
- Dividend Yield
- NPWR N/A
- MREO N/A
- EPS Growth
- NPWR N/A
- MREO N/A
- EPS
- NPWR 0.11
- MREO N/A
- Revenue
- NPWR $250,000.00
- MREO $1,000,000.00
- Revenue This Year
- NPWR N/A
- MREO $16.39
- Revenue Next Year
- NPWR $7,463.34
- MREO $9.44
- P/E Ratio
- NPWR $119.91
- MREO N/A
- Revenue Growth
- NPWR 38.12
- MREO N/A
- 52 Week Low
- NPWR $6.57
- MREO $1.86
- 52 Week High
- NPWR $14.28
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- NPWR 75.83
- MREO 28.70
- Support Level
- NPWR $8.63
- MREO $4.05
- Resistance Level
- NPWR $14.28
- MREO $4.40
- Average True Range (ATR)
- NPWR 0.92
- MREO 0.19
- MACD
- NPWR 0.40
- MREO -0.06
- Stochastic Oscillator
- NPWR 72.60
- MREO 2.81
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system which it refers to as the "NET Power Cycle is designed to produce clean, reliable and low-cost electricity from natural gas while capturing virtually all atmospheric emissions.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).